Aviva PLC Biogen Inc. Transaction History

Aviva PLC

$28.3 Billion
Q1 2024

A detailed history of Aviva PLC transactions in Biogen Inc. stock. As of the latest transaction made, Aviva PLC holds 32,123 shares of BIIB stock, worth $7.45 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

32,123

Previous 66,959 52.03%

Holding current value

$7.45 Million

Previous $17.3 Million 60.03%

% of portfolio

0.02%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $7.39 Million - $9.33 Million	-34,836 Reduced 52.03%	32,123 $6.93 Million
Q4 2023 Feb 09, 2024	BUY	$222.59 - $267.94 $3.96 Million - $4.76 Million	17,770 Added 36.13%	66,959 $17.3 Million
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $2.04 Million - $2.31 Million	-8,072 Reduced 14.1%	49,189 $12.6 Million
Q2 2023 Aug 10, 2023	BUY	$275.25 - $318.06 $6.74 Million - $7.79 Million	24,493 Added 74.75%	57,261 $16.3 Million
Q1 2023 May 12, 2023	SELL	$256.56 - $292.34 $3.41 Million - $3.89 Million	-13,292 Reduced 28.86%	32,768 $9.11 Million

Q4 2022 Feb 09, 2023	BUY	$252.44 - $306.72 $6.09 Million - $7.4 Million	24,112 Added 109.86%	46,060 $12.8 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $610,937 - $842,427	-3,138 Reduced 12.51%	21,948 $5.86 Million
Q2 2022 Aug 04, 2022	SELL	$187.54 - $223.02 $2.3 Million - $2.74 Million	-12,283 Reduced 32.87%	25,086 $5.12 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $1.69 Million - $2.13 Million	-8,733 Reduced 18.94%	37,369 $7.87 Million
Q4 2021 Feb 10, 2022	SELL	$223.92 - $287.77 $789,765 - $1.01 Million	-3,527 Reduced 7.11%	46,102 $11.1 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $302,516 - $394,514	1,069 Added 2.2%	49,629 $14 Million
Q2 2021 Aug 10, 2021	SELL	$259.0 - $414.71 $523,957 - $838,958	-2,023 Reduced 4.0%	48,560 $16.8 Million
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $391,149 - $458,254	-1,610 Reduced 3.08%	50,583 $14.2 Million
Q4 2020 Feb 10, 2021	BUY	$236.26 - $355.63 $280,676 - $422,488	1,188 Added 2.33%	52,193 $12.8 Million
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $848,058 - $979,189	-3,203 Reduced 5.91%	51,005 $14.5 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $1.78 Million - $2.36 Million	-6,890 Reduced 11.28%	54,208 $14.5 Million
Q1 2020 May 14, 2020	SELL	$268.85 - $341.04 $736,111 - $933,767	-2,738 Reduced 4.29%	61,098 $19.3 Million
Q4 2019 Feb 10, 2020	SELL	$220.06 - $304.07 $253,729 - $350,592	-1,153 Reduced 1.77%	63,836 $18.9 Million
Q3 2019 Nov 12, 2019	SELL	$217.44 - $243.88 $1.55 Million - $1.74 Million	-7,132 Reduced 9.89%	64,989 $15.1 Million
Q2 2019 Jul 30, 2019	SELL	$219.29 - $241.72 $512,480 - $564,899	-2,337 Reduced 3.14%	72,121 $16.9 Million
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $339,584 - $531,150	-1,567 Reduced 2.06%	74,458 $17.6 Million
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $5.99 Million - $7.59 Million	-21,516 Reduced 22.06%	76,025 $22.9 Million
Q3 2018 Nov 13, 2018	SELL	$293.51 - $383.83 $2.63 Million - $3.44 Million	-8,962 Reduced 8.41%	97,541 $34.5 Million
Q2 2018 Aug 01, 2018	SELL	$257.52 - $306.91 $357,695 - $426,297	-1,389 Reduced 1.29%	106,503 $30.9 Million
Q1 2018 May 14, 2018	SELL	$260.13 - $367.91 $2.63 Million - $3.71 Million	-10,095 Reduced 8.56%	107,892 $29.5 Million
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $5.34 Million - $5.99 Million	-17,373 Reduced 12.83%	117,987 $37.6 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $185,558 - $217,595	660 Added 0.49%	135,360 $42.4 Million
Q2 2017 Aug 07, 2017	BUY	N/A	134,700	134,700 $36.5 Million

Others Institutions Holding BIIB

# of Institutions

1,046

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account